High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

被引：0
|
作者：
Maryam Pourabdollah
Mohammad Bahmanyar
Eshetu G. Atenafu
Donna Reece
Jian Hou
Hong Chang
机构：
[1] University of Toronto,Department of Laboratory Medicine and Pathobiology
[2] University of Toronto,Department of Biostatistics
[3] University of Toronto,Department of Hematology and Medical Oncology
[4] Shanghai Chang Zheng Hospital,Department of Hematology
[5] University Health Network,Department of Laboratory Hematology
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Multiple Myeloma; Myeloma; Myeloma Cell; Lenalidomide; Myeloma Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy.
引用
收藏
相关论文
共 50 条
  • [31] TREATMENT OF MULTIPLE RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE DEXAMETHASONE RETROSPECTIVE ANALYSIS OF 65 PATIENTS TREATED AT A CENTER
    Moya Arnao, M.
    Cabanas Perianes, V
    Moreno Balmonte, M. J.
    Martinez Marin, A.
    Fernandez Poveda, E.
    Navarro Almenzar, B.
    Berenguer Piqueras, M.
    Salido Fierez, E.
    Labbadia, F.
    Perez Lopez, R.
    Garcia Hernandez, A. M.
    Cerezo Manchado, J. J.
    Blanquer Blanquer, M.
    Martinez Garcia, A. B.
    Melero Amor, A.
    Garcia Candel, F.
    Moraleda Jimenez, J. M.
    HAEMATOLOGICA, 2017, 102 : 97 - +
  • [32] A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Turner, Carley
    Swift, Regina A.
    Eades, Benjamin M.
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert A.
    Lim, Stephen
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
  • [34] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [35] A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura V.
    Moss, Robert A.
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Greenwald, Daniel
    Boccia, Ralph V.
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2019, 134
  • [36] Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Sun, Haowei
    Atenafu, Eshetu G.
    Yeboah, Elizabeth
    Reece, Donna E.
    Trudel, Suzanne
    Kukreti, Vishal
    Masih-Khan, Esther
    Winter, Andrew
    Chen, Christine
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 407 - 414
  • [37] Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
    Barbee, Meagan S.
    Nooka, Ajay
    Kaufman, Jonathan L.
    Kim, Sungjin
    Chen, Zhengjia
    Heffner, Leonard T., Jr.
    Lonial, Sagar
    Harvey, R. Donald
    CANCER, 2015, 121 (06) : 853 - 862
  • [38] Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
    Chang, Hong
    Jiang, Allan
    Qi, Connie
    Trieu, Young
    Chen, Christine
    Reece, Donna
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 2084 - 2091
  • [39] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    BLOOD, 2007, 110 (11) : 128A - 128A
  • [40] EFFECT OF CONTINUING LENALIDOMIDE TREATMENT ON SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA A CLINICAL PRACTICE CHART REVIEW
    Stefanikova, Z.
    Flochova, E.
    Guman, T.
    Hlebaskova, M.
    Hrabovska, E.
    Chudej, J.
    Kafkova, A.
    Lorencikova, M.
    Markuliak, I.
    Masarova, K.
    Sajgalikova, H.
    Simek, M.
    Svorcova, E.
    Tothova, E.
    Valekova, L.
    HAEMATOLOGICA, 2012, 97 : 616 - 617
12345